Eton Q1 2022 Earnings Report
Key Takeaways
Eton Pharmaceuticals reported a net loss of $5.3 million for the first quarter of 2022, with product sales and royalty revenue of $2.2 million. The company is experiencing growth in ALKINDI SPRINKLEĀ® and the launch of carglumic acid and RezipresĀ®.
Reported fifth straight quarter of sequential growth in product sales.
Carglumic acid product launched in late-December 2021 received a favorable reception.
ALKINDI SPRINKLEĀ® continues to grow and reported record quarterly revenue.
Eton expects 2022 revenue of at least $25 million, including $10 million of milestone payments and $15 million of product sales and royalties.
Eton
Eton
Forward Guidance
Eton expects 2022 revenue of at least $25 million, including $10 million of milestone payments and $15 million of product sales and royalties.